<DOC>
	<DOCNO>NCT00019383</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Giving vaccine interleukin-2 sargramostim may help kill tumor cell . PURPOSE : Phase II trial study effectiveness peptide vaccine without adjuvant interleukin-2 sargramostim treat patient recurrent refractory metastatic melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Recurrent Refractory Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether patient refractory metastatic melanoma undergo partial complete response peptide specific HLA-antigen , either alone combine 1 3 adjuvant . - Evaluate immunologic response peptide alone combine 1 3 adjuvant patient . OUTLINE : Patients stratify HLA status ( A1 vs A3 v A24 v A31 ) . Patients assign 1 4 vaccine group : - Group 1 ( HLA-A1 positive ) : Patients receive tyrosinase:240-251 . - Group 2 ( HLA-A3 positive ) : Patients receive gp100:17-25 . ( close accrual 5/17/2000 ) - Group 3 ( HLA-A24 positive ) : Patients receive tyrosinase:206-214 . - Group 4 ( HLA-A31 positive ) : Patients receive tyrosinase relate protein-1 . Each peptide vaccine separately emulsify Montanide ISA-51 administer subcutaneously thigh . Patients treat peptide vaccine alone combine 1 3 possible adjuvant ( interleukin-2 ( IL-2 ) IV , IL-2 delay IV , sargramostim ( GM-CSF ) SQ ) depend time entry study response treatment . At least 4 6 patient accrued peptide alone cohort begin accrual cohort . Any patient experience unacceptable toxicity due adjuvant therapy take study . If second patient develop unacceptable toxicity , schedule peptide administration discontinue . Patients exhibit stable , minor , mixed , partial response may receive 12 additional course . Patients follow 4-6 week . PROJECTED ACCRUAL : A maximum 457 patient accrue study 3.5 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven refractory metastatic melanoma Must HLAA1 , HLAA3 , HLAA24 , HLAA31 positive Measurable disease PATIENT CHARACTERISTICS : Age : 16 Performance Status : ECOG 01 Life Expectancy : Greater 3 month Hematopoietic : WBC least 3,000/mm^3 Platelet count least 90,000/mm^3 No coagulation disorder Hepatic : AST ALT less 2 time upper limit normal Bilirubin great 1.6 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : No major cardiovascular disease Pulmonary : No major respiratory disease Other : Not pregnant Fertile patient must use effective contraception HIV negative Hepatitis B surface antigen negative No known allergy Montanide ISA51 No active systemic infection No immunodeficiency disease PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy No concurrent biologic therapy Chemotherapy : At least 3 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 3 week since prior endocrine therapy No concurrent steroid therapy endocrine therapy Radiotherapy : At least 3 week since prior radiotherapy No concurrent radiotherapy Surgery : Prior concurrent surgery melanoma allow</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2003</verification_date>
	<keyword>recurrent melanoma</keyword>
</DOC>